Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Xin Gao; David F McDermott; M Dror Michaelson

doi:10.1634/theoncologist.2019-0165

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29.

Authors

Xin Gao¹, David F McDermott², M Dror Michaelson³

Affiliations

¹ Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA xgao4@partners.org.
² Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
³ Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

Abstract

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / pharmacology*
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Renal Cell / blood supply
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / immunology
Clinical Trials, Phase III as Topic
Drug Synergism
Humans
Immunotherapy / methods*
Kidney Neoplasms / blood supply
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / immunology
Models, Biological
Neovascularization, Pathologic / drug therapy
Neovascularization, Pathologic / immunology
Neovascularization, Pathologic / prevention & control
Prognosis
Randomized Controlled Trials as Topic

Substances

Angiogenesis Inhibitors
Antineoplastic Agents, Immunological